Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Increased circulating thyroglobulin concentration, Delayed speech and language development, Increased circulating free T4 concentration, and Increased circulating free T3 and others; and common findings: Attention deficit hyperactivity disorder.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lab test results | 2 | Increased circulating thyroglobulin concentration, Increased circulating free T4 concentration |
THRB function has not been fully characterized.
Thyroid hormone resistance, generalized, autosomal dominant is associated with mutations in the THRB gene on chromosome 3.
Genetic testing for THRB is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for thyroid hormone resistance, generalized, autosomal dominant has been reported in the published literature.
Phenotype severity distribution: 6 always present features, 1 common feature.
3 clinical trials registered, 2 recruiting. Pipeline includes 1 PHASE3.
73 publications have been identified in PubMed for thyroid hormone resistance, generalized, autosomal dominant. Research spans Case Report / Case Series (44%), Epidemiology / Natural History (25%), and Basic Science / Preclinical (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 32 | 44% |
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 4:02 PM UTC
Online Mendelian Inheritance in Man
Brain and nerves | 1 | Delayed speech and language development |
Hormones | 1 | Impaired sensitivity to thyroid hormone |
Disease patterns and progression
18 |
25% |
Laboratory research | 13 | 18% |
Research summaries | 5 | 7% |
New treatment approaches | 4 | 5% |
Testing and diagnosis research | 1 | 1% |
Shelly M (2026). [PMID: 41837232](https://pubmed.ncbi.nlm.nih.gov/41837232/). *JCEM Case Rep*. [Case Report / Case Series]
Yang Z (2026). [PMID: 42065173](https://pubmed.ncbi.nlm.nih.gov/42065173/). *Medicine (Baltimore)*. [Review / Meta-Analysis]
Đukić M (2026). [PMID: 42045985](https://pubmed.ncbi.nlm.nih.gov/42045985/). *Cardiovasc Diabetol Endocrinol Rep*. [Diagnostic / Biomarker]
Wu X (2026). [PMID: 42237874](https://pubmed.ncbi.nlm.nih.gov/42237874/). *Biol Open*. [Basic Science / Preclinical]
Li C (2026). [PMID: 41739686](https://pubmed.ncbi.nlm.nih.gov/41739686/). *The oncologist*. [Epidemiology / Natural History]
Möller L (2026). [PMID: 41824051](https://pubmed.ncbi.nlm.nih.gov/41824051/). *Inn Med (Heidelb)*. [Review / Meta-Analysis]
Koo TH (2026). [PMID: 41641293](https://pubmed.ncbi.nlm.nih.gov/41641293/). *AACE endocrinology and diabetes*. [Basic Science / Preclinical]
Moran C (2026). [PMID: 41131705](https://pubmed.ncbi.nlm.nih.gov/41131705/). *J Clin Endocrinol Metab*. [Gene Therapy / Novel Therapeutics]
Awad MH (2026). [PMID: 42228305](https://pubmed.ncbi.nlm.nih.gov/42228305/). *Endocrine*. [Case Report / Case Series]
Pan YA (2026). [PMID: 41971634](https://pubmed.ncbi.nlm.nih.gov/41971634/). *JCEM Case Rep*. [Case Report / Case Series]